{"entity":{"id":"mecapegfilgrastim","kind":"drug","name":"Mecapegfilgrastim","aka":["Aiduo","19K"],"tldr":"Mecapegfilgrastim is Hengrui's long-acting G-CSF, approved in China in 2018 to prevent chemotherapy-induced neutropenia.","summary":"Mecapegfilgrastim (Aiduo) is a long-acting pegylated G-CSF developed by Jiangsu Hengrui. The NMPA approved it in May 2018 to reduce the incidence and duration of neutropenia in patients receiving myelosuppressive chemotherapy for non-myeloid cancers. It is one of the most widely used supportive-care biologics in China.","status":"approved","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov: trials of mecapegfilgrastim","url":"https://clinicaltrials.gov/search?intr=mecapegfilgrastim"}],"tags":["china","nmpa-approved"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["hengrui"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"provenance":{"editedBy":"OnCo China deep dive","editedOn":"2026-09-16"},"code":"HHPG-19K","modality":"Long-acting granulocyte colony-stimulating factor (growth factor support)","mechanism":"A pegylated form of G-CSF that tells the bone marrow to make neutrophils, shortening the low-neutrophil period after chemotherapy.","approvals":[{"region":"CN","year":2018,"indication":"Prevention of chemotherapy-induced neutropenia in non-myeloid cancers"}],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/mecapegfilgrastim/","neighbours":{"company":[{"id":"hengrui","kind":"company","name":"Jiangsu Hengrui Pharmaceuticals","route":"/companies/hengrui/"}]}}